Education
About Us
Working with TipRanks
Follow Us
PetVivo Holdings (PETV)
OTHER OTC:PETV
Top Page
PetVivo Holdings
(OTC:PETV)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.99
▼(-12.05% Downside)
The score is held down primarily by deep unprofitability and continued cash burn, with weak technical momentum reinforcing near-term risk. Offsetting positives include low leverage/liability reduction and encouraging revenue growth and strategic progress highlighted on the earnings call, while valuation is difficult to assess meaningfully due to negative earnings.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful product adoption and market expansion, supporting long-term business sustainability.
Debt Reduction
Significant debt reduction improves financial stability and flexibility, enhancing the company's ability to invest in growth opportunities.
New Product Launch
The new AI platform could significantly lower costs and increase customer acquisition, boosting long-term profitability and market reach.
Negative Factors
Profitability Challenges
Ongoing losses highlight challenges in achieving profitability, which may hinder long-term financial health and investment capacity.
Decreased Gross Margin
A reduced gross margin could pressure profitability, necessitating cost management to maintain financial performance.
Slow Market Adoption
Slow product adoption may limit revenue growth and market penetration, impacting long-term business expansion and competitiveness.
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.92M
Dividend YieldN/A
Average Volume (3M)21.60K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth45.45%
EPS Growth20.31%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.11
Shares Outstanding33,580,630
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue21.05
Enterprise Value/Gross Profit26.68
Enterprise Value/Ebitda-3.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PetVivo Holdings Business Overview & Revenue Model
Company DescriptionPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyPetVivo Holdings generates revenue primarily through the sale of its flagship product, Spryng with OsteoCushion Technology, which is marketed to veterinary clinics and pet health professionals for the treatment of osteoarthritis in dogs. The company employs a direct sales model and collaborates with veterinary distributors to reach a broader market. Additionally, PetVivo may explore partnerships with veterinary hospitals and clinics to facilitate product adoption and increase sales volume. The company’s revenue model also includes potential licensing agreements or collaborations with other companies in the animal health sector, which could provide supplementary income streams.
PetVivo Holdings Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, international expansion, and strategic partnerships, which are positive indicators for future prospects. However, increased net loss and slow adoption in certain market segments present challenges.Q2-2026 Updates
Positive Updates
Revenue Growth and Record Quarter
Revenues reached $303,000, marking a 51% increase over the first quarter of the previous year and an 85% increase for the first half compared to the previous year. This was the highest revenue-generating fiscal second quarter on record.
Expansion into International Markets
PetVivo expanded its market reach into Europe and Mexico, with significant growth potential in both regions. The UK market is growing at a 7.8% CAGR, and the Mexican market is projected to grow at an 8.6% CAGR.
Introduction of New Products
The commercialization of PRECISE PRP for dogs and horses increased revenue, with a promising outlook for its equine market reintroduction. PRECISE PRP accounted for 42% of revenue in the last quarter.
Strategic Partnerships and Alliances
PetVivo formed strategic alliances with Commonwealth Markets and Digital Landia, enhancing product promotion and integrating AI technology for veterinary diagnostics.
Debt Reduction and Financial Improvements
Total liabilities reduced by 79% to $1.1 million from $5.1 million, primarily due to the extinguishment of derivative liabilities and conversion of convertible notes to common stock.
Trading on OTCQX Best Market
PetVivo qualified to trade on the OTCQX Best Market, enhancing visibility, liquidity, and accessibility for investors.
Negative Updates
Increased Net Loss
Net loss totaled $3 million compared to $2.2 million in the same year-ago quarter, primarily due to an increase in interest expense from debt discount related to convertible notes.
Decreased Gross Margin
Gross profit decreased from 89.5% to 72.6% due to the sales mix including the new PRECISE PRP product, which carries a smaller margin.
Slow Adoption in Companion Animal Market
The adoption of products like Spring and PRECISE PRP in companion animal clinics is progressing slowly, with a lengthy learning curve for veterinarians.
Company Guidance
During the recent call, PetVivo provided comprehensive guidance on its financial performance and strategic initiatives for the fiscal second quarter of 2026. The company reported a 51% increase in quarterly revenues to $303,000 compared to the first quarter of the previous year, with a notable 85% rise in first-half revenues exceeding $600,000. This growth was driven by a 35% increase in sales from the expanded North American distributor network, accounting for 75% of quarterly revenues, and the introduction of new product offerings like PRECISE PRP. The company highlighted a gross profit of $220,000, representing 72.6% of revenues, and a decrease in operating expenses by 3% to $2.3 million, resulting in a 5% reduction in operating loss. Additionally, the net loss was $3 million, or $0.11 per share, due to increased interest expenses from debt discount, although excluding this, the net loss improved by 5% to $2.1 million. PetVivo's available cash increased to $768,000, and total liabilities dramatically decreased by 79% to $1.1 million. The company also emphasized its strategic efforts, including the commercialization of PRECISE PRP for equine markets, expansion into European markets through the Nupsila Group, and a strategic collaboration with Commonwealth Markets. Moreover, PetVivo announced its qualification to trade on the OTCQX Best Market, enhancing its visibility within the investment community. Looking ahead, PetVivo anticipates continued strong sales momentum, expecting record growth for the full fiscal year ending March 31, 2026, as it continues to expand the use of its flagship products, Spring with OsteoCushion technology and PRECISE PRP.PetVivo Holdings Financial Statement Overview
Summary
PetVivo Holdings is experiencing revenue growth, but profitability and cash flow remain significant challenges. The company has improved its leverage position but needs to focus on enhancing operational efficiency and cash flow generation to achieve financial stability.Income Statement
PetVivo Holdings has shown some revenue growth, with an 18.46% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is relatively high at 87.84%, but the company needs to manage its operating expenses better to improve overall profitability.Balance Sheet
The company's debt-to-equity ratio has improved to 0.69, indicating better leverage management compared to previous years. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company has a reasonable level of stockholders' equity relative to its total assets.Cash Flow
PetVivo Holdings has a positive free cash flow to net income ratio, suggesting that it is generating cash flow relative to its net losses. However, the operating cash flow remains negative, and the company needs to improve its cash flow from operations to ensure sustainability.| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.41M | 1.13M | 968.71K | 917.16K | 115.59K | 12.58K |
| Gross Profit | 1.11M | 994.86K | 739.53K | 390.35K | -85.57K | 1.88K |
| EBITDA | -7.52M | -7.69M | -10.49M | -8.62M | -4.99M | -1.87M |
| Net Income | -9.50M | -8.40M | -10.96M | -8.70M | -4.94M | -3.75M |
Balance Sheet | ||||||
| Total Assets | 5.26M | 9.34M | 3.12M | 2.44M | 7.43M | 835.25K |
| Cash, Cash Equivalents and Short-Term Investments | 767.91K | 377.69K | 87.40K | 475.31K | 6.11M | 23.58K |
| Total Debt | 86.32K | 2.90M | 1.37M | 345.33K | 332.85K | 732.53K |
| Total Liabilities | 1.08M | 5.12M | 2.43M | 1.71M | 1.44M | 1.73M |
| Stockholders Equity | 4.18M | 4.22M | 685.95K | 725.02K | 5.99M | -896.98K |
Cash Flow | ||||||
| Free Cash Flow | -6.56M | -5.89M | -7.73M | -7.22M | -4.36M | -1.21M |
| Operating Cash Flow | -6.02M | -5.32M | -7.42M | -6.79M | -4.17M | -1.05M |
| Investing Cash Flow | -538.23K | -563.43K | -309.10K | -423.93K | -183.18K | -160.16K |
| Financing Cash Flow | 7.20M | 6.03M | 7.34M | 1.59M | 10.44M | 1.22M |
PetVivo Holdings Technical Analysis
Negative
1.12
Price Trends
1.18
Negative
1.13
Negative
0.92
Positive
Market Momentum
-0.03
Positive
38.78
Neutral
35.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.18, and above the 200-day MA of 0.92, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 35.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PetVivo Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.38M | -0.21 | -127.95% | ― | -2.02% | -32.93% | |
48 Neutral | $18.52M | -1.05 | -335.47% | ― | 18.76% | 60.09% | |
47 Neutral | $33.92M | -2.53 | -379.92% | ― | 45.45% | 20.31% | |
46 Neutral | $19.77M | -4.89 | -139.29% | ― | 4.58% | 55.26% | |
44 Neutral | $15.56M | -0.25 | ― | ― | -50.49% | 39.93% |
* Healthcare Sector Average
PETV
PetVivo Holdings
1.00
0.06
6.38%
IRIX
Iridex
1.48
-0.13
-8.07%
LFWD
Lifeward
0.63
-0.83
-56.92%
VVOS
Vivos Therapeutics
2.07
-2.99
-59.09%
ALUR
Allurion Technologies
1.84
-1.30
-41.40%
NXL
Nexalin Technology, Inc.
0.71
-2.07
-74.46%
PetVivo Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
PetVivo Holdings to Present at Investor Conferences
Neutral
Nov 3, 2025
PetVivo Holdings, Inc. has announced its intention to present information at investor conferences and other forums, which may include details from an attached investor presentation. This information, disclosed under SEC regulations, will be shared with investors, analysts, and on the company’s website, though it is not considered filed with the SEC and may be updated as needed.
The most recent analyst rating on (PETV) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on PetVivo Holdings stock, see the PETV Stock Forecast page.
Business Operations and StrategyExecutive/Board Changes
PetVivo Holdings Expands Board with New Appointment
Positive
Oct 30, 2025
On October 28, 2025, PetVivo Holdings, Inc. announced the appointment of Josh Ruben to its Board of Directors, expanding the board from seven to eight members. Ruben, who brings extensive experience in healthcare finance and life sciences, is expected to contribute significantly to PetVivo’s growth and market presence. His background in executing multi-billion-dollar transactions and strategic insights into growth-stage companies will support PetVivo’s mission to deliver innovative solutions for osteoarthritis and other joint conditions in companion animals.
The most recent analyst rating on (PETV) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on PetVivo Holdings stock, see the PETV Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.